These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23497810)

  • 1. The placebo response in clinical trials-the current state of play.
    Enck P; Klosterhalfen S
    Complement Ther Med; 2013 Apr; 21(2):98-101. PubMed ID: 23497810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized placebo-controlled cross-over designs in clinical trials: a gold standard to be reassessed.
    Leonard G; Lafrenaye S; Goffaux P
    Curr Med Res Opin; 2012 Feb; 28(2):245-8. PubMed ID: 22208674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The placebo effect revisited: lessons learned to date.
    Kirsch I
    Complement Ther Med; 2013 Apr; 21(2):102-4. PubMed ID: 23497811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials.
    Wampold BE; Minami T; Tierney SC; Baskin TW; Bhati KS
    J Clin Psychol; 2005 Jul; 61(7):835-54. PubMed ID: 15827993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veterinary clinical research database for homeopathy: placebo-controlled trials.
    Clausen J; Albrecht H; Mathie RT
    Complement Ther Med; 2013 Apr; 21(2):115-20. PubMed ID: 23497815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.
    Tedeschini E; Fava M; Goodness TM; Papakostas GI
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):562-7. PubMed ID: 20219330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial designs and exploration of the placebo response.
    Dieppe P
    Complement Ther Med; 2013 Apr; 21(2):105-8. PubMed ID: 23497812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs.
    Kube T; Rief W
    Drug Discov Today; 2017 Apr; 22(4):729-735. PubMed ID: 27919806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questioning the methodologic superiority of 'placebo' over 'active' controlled trials.
    Howick J
    Am J Bioeth; 2009 Sep; 9(9):34-48. PubMed ID: 19998192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose finding with the sequential parallel comparison design.
    Wang JJ; Ivanova A
    J Biopharm Stat; 2014; 24(5):1091-101. PubMed ID: 24919070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The placebo revisited: what we do, don't and maybe won't know.
    van Haselen R
    Complement Ther Med; 2013 Apr; 21(2):83-4. PubMed ID: 23497807
    [No Abstract]   [Full Text] [Related]  

  • 16. Placebo in clinical trials.
    Ito S
    Clin Pharmacol Ther; 2011 Nov; 90(5):637-9. PubMed ID: 22012308
    [No Abstract]   [Full Text] [Related]  

  • 17. Is the placebo powerless?
    Kupers R
    N Engl J Med; 2001 Oct; 345(17):1278; author reply 1278-9. PubMed ID: 11680457
    [No Abstract]   [Full Text] [Related]  

  • 18. Placebo responses in randomized trials of antiepileptic drugs.
    Guekht AB; Korczyn AD; Bondareva IB; Gusev EI
    Epilepsy Behav; 2010 Jan; 17(1):64-9. PubMed ID: 19919904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature and power of the placebo effect.
    Miller FG; Rosenstein DL
    J Clin Epidemiol; 2006 Apr; 59(4):331-5. PubMed ID: 16549251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Critical of the additive model of the randomized controlled trial].
    Boussageon R; Gueyffier F; Bejan-Angoulvant T; Felden-Dominiak G
    Therapie; 2008; 63(1):29-35. PubMed ID: 18387273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.